Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

663
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
663
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Under- and overdosing insulin in the hospital: A retrospective cohort study of dose deviation and patient outcomes.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Reply to Improda, N.; Ballarin, G. Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on "Zaitoon et al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. <i>Children</i> 2025, <i>12</i>, 1427".

Children (Basel, Switzerland)·2026
Same author

Renal Lipotoxicity: Mechanisms and Therapeutic Perspectives.

Diabetes care·2026
Same author

QT interval changes in transgender/gender diverse adolescents receiving gonadotropin-releasing hormone agonist and gender-affirming hormonal treatment.

International journal of transgender health·2026
Same author

Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects.

Nature reviews. Nephrology·2026
Same author

Sex Differences in the Association Between Body Composition and Cognitive Performance in Adolescents With Type 1 Diabetes.

Diabetes/metabolism research and reviews·2026

Related Experiment Video

Updated: Jan 10, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

885

Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.

Hussein Zaitoon1, Aimee D Wauters1, Luisa M Rodriguez1

  • 1Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX 78229, USA.

Children (Basel, Switzerland)
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for pediatric obesity and type 2 diabetes (T2D), effectively reducing weight and BMI. However, careful monitoring is crucial due to potential impacts on musculoskeletal health and nutritional status.

Keywords:
GLP-1 receptor agonistsbody compositionliraglutidepediatric obesitysemaglutide

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589
Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice
11:16

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice

Published on: May 3, 2012

22.7K

Related Experiment Videos

Last Updated: Jan 10, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

885
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589
Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice
11:16

Progressive-ratio Responding for Palatable High-fat and High-sugar Food in Mice

Published on: May 3, 2012

22.7K

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for pediatric obesity and type 2 diabetes (T2D).
  • Evidence synthesis is needed to evaluate their efficacy and safety in children and adolescents.

Purpose of the Study:

  • To review current evidence on GLP-1RA efficacy and safety in pediatric obesity and T2D.
  • To identify knowledge gaps and guide future research for pediatric anti-obesity therapies.

Main Methods:

  • Structured review of randomized controlled trials, extension studies, and mechanistic investigations.
  • Focused on outcomes including body weight, BMI, body composition, glycemic control, and adverse events in pediatric populations.

Main Results:

  • GLP-1RAs (liraglutide, semaglutide) significantly reduce BMI and weight in adolescents and younger children.
  • Weight loss includes lean mass; potential risks include impaired muscle strength and bone density without exercise and adequate protein.
  • Gastrointestinal events are common; long-term effects on growth, puberty, and nutritional status remain largely unaddressed.

Conclusions:

  • GLP-1RAs are a valuable adjunct to lifestyle interventions for pediatric obesity.
  • Pediatric-specific protocols are essential to address musculoskeletal health, nutritional adequacy, and misuse.
  • Further research is critical for pediatric pharmacokinetics, dosing, and long-term developmental safety to establish evidence-based guidelines.